4th Nov 2014 08:27
LONDON (Alliance News) - Physiomics PLC shares surged higher early Tuesday after the company disclosed that US pharmaceutical company Merck & Co Inc is a partner.
Merck published a paper in CPT: Pharmacometrics and Systems Biology in which the company specified Physiomics' Virtual Tumour platform as a technology which helped the company's decision-making progress.
"We are extremely pleased to be able to reveal the name of one of our large pharma customers," said Mark Chadwick, chief executive of Physiomics.
Shares in Physiomics were up 20% to 0.145 pence in early trade Tuesday, making it the best performer in the AIM All-Share index.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Physiomics